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SUMMARY 
The authors report a term male neonate who was born in unexpectedly poor condition with low Apgar 
scores and low venous cord gas pH. He required admission to the neonatal unit and was found to have 
developed haemolytic anaemia with associated hydrops, following a presumed severe antenatal insult. 
Antenatally, low levels of anti-E antibodies (titre 8) had been detected at 28 weeks’ gestation. Following 
the British Society for Haematology and local neonatal team guidance, advice was given for cord direct 
antiglobulin test, full blood count and bilirubin at delivery. This case highlights the rare case of 
haemolytic disease of the fetus and newborn on a background of maternal low titre anti-E antibodies. 
 
BACKGROUND 
This is a report of a neonate who was unexpectedlyfound to have developed haemolytic anaemia with 
significant hydrops, likely secondary to a severe antenatal insult, requiring admission to the neonatal 
unit. Antenatally, the presence of low levels of anti-E antibodies was detected at the 28-week maternal 
bloods. E antigen belongs to the Rhesus (Rh) blood group system, and after anti-D, anti-c and anti-K, 
anti-E can also commonly causes haemolytic disease of the fetus and newborn (HDFN). However, from 
the current literature, in the absence of a history of 
HDFN, the severity of haemolysis and thus likelihood of developing hydrops appears low. Yet this case 
shows that hydrops with fetal compromise can develop in the presence of lower anti-E titres. 
The current guidance from the Royal College of Obstetricians and Gynaecologists and the British 
Society for Haematology is that 
“clinically significant antibodies, other than anti-D, -c or -K, should be excluded or, if present, 
assessed by titration at the booking appointment and at 28weeks’ gestation. If deemed 
necessary based on a high titre (>32) and/or a past history of HDFN, referral to a specialist in 
fetal medicine should be made for further assessment”. 
 
CASE PRESENTATION 
The patient was the second child of a 26-year-old woman. The mother had one previous pregnancy 
which was uncomplicated antenatally resulting in a normal delivery of a 3.09 kg live baby at term. In the 
present pregnancy, she booked at 8 weeks’ gestation. She had normal dating and fetal anomaly scans. 
There was no maternal history of epilepsy or seizures during the pregnancy and no history of drug 
misuse. She had a further growth scan at 28 weeks’ gestation because the symphyseal fundal height 
plotted <10th centile on a customised growth chart. This growth scan was normal. The 28-week blood 
tests detected a low titre of anti-E antibody of 8. The recommendation from the blood transfusion 
laboratory was for a cord direct antiglobulin test (DAT) at delivery and no further action. A neonatal 
alert was sent which further advised a full blood count and bilirubin in addition to cord blood DAT at 
delivery. She had two further contacts antenatally for a single episode of reduced fetal movements and 
thrush at 36+1/40 and 38+1/40, respectively.  
 
At 39+1 weeks’ gestation, she presented to obstetric care with contractions and was found to be 2–3 cm 
dilated. She progressed well and delivered a live male infant 14 hours later. Despite being born in 
apparently good condition initially, the baby collapsed at 1 min of life and required resuscitation 
including ventilation breaths and facial continuous positive airway pressure (CPAP). Apgar scores were 
0 at birth, 4 at 5 min, and 8 at 10 min. A single cord gas was obtained with pH 7.123, base excess of 
−14.2, lactate of 12.1 mmol/L and haemoglobin of 41 g/L. Cord DAT was IgG 4+ positive with a raised 
total bilirubin (134 µmol/L) and a Kleihauer test <4 mL, leading to a diagnosis of HDFN. 
 
Birth weight was 2.5 kg (second centile). The baby had signs of moderate hypoxic-ischaemic 
encephalopathy and was admitted to the neonatal unit for whole body hypothermia (33.0°C–34.0°C), 
CPAP and inotropic support. On examination he had mild ascites with body wall oedema and 
hepatomegaly. 
 
INVESTIGATIONS 
Admission haemoglobin confirmed congenital anaemia (haemoglobin of 64 g/L). Other admission blood 
test results showed abnormal coagulation (prothrombin time 20.2 s, fibrinogen 1.2 g/L), severe 
thrombocytopaenia (platelet count 33x109/L), mildly abnormal liver function tests (alanine transaminase 
(ALT) 103 U/L; gamma-glutamyltransferase (GGT) 67 U/L; albumin 21 g/L), total bilirubin of 134 
µmol/L, conjugated bilirubin of 48µmol/L and acute renal failure. On ophthalmological examination the 
baby was also found to have bilateral posterior embryotoxon, and echocardiography showed branch 
pulmonary arterial stenosis. A magnetic resonance brain scan done on day 14 showed a structurally 
normal brain and no features to suggest any hypoxic-ischaemic brain injury. 
TREATMENT 
To treat the anaemia and high unconjugated jaundice, he received exchange blood transfusion, for which 
he was electively intubated, and phototherapy. He received intramuscular vitamin K and also received 
fresh frozen plasma to treat the prolonged prothrombin time. Metabolic acidosis was corrected by 
bicarbonate and he was administered intravenous glucose to maintain normoglyceamia prior to 
introduction of enteral feeds on day 4. 
Because of the early and persistent conjugated hyperbilirubinaemia and hepatosplenomegaly, advice was 
sought from a tertiary paediatric hepatology centre, which recommended ursodeoxycholic acid, vitamin 
E and vitamin K supplementation. He received human albumin solution with fluid restriction, to which 
his renal function, oedema and fluid balance responded and improved. 
Phenobarbital was started on day 1 due to clinical and electrical seizures. Initial rewarming was 
attempted after 72 hours; however, due to increased seizures on rewarming, he was cooled for a further 
12 hours. Levetiracetam and midazolam were added for persisting seizures. After day 10, midazolam 
infusion was weaned without recurrence of seizures. Dobutamine was stopped on day 5, and the baby 
remained haemodynamically stable. He was extubated on day 22 and was self-ventilating in air with no 
supplementary oxygen requirement by day 31. 
OUTCOME AND FOLLOW-UP 
On review at 5 months of age, he was thriving with accelerating growth and had no neurological 
sequelae. He was successfully weaned off levetiracetam and has remained seizure-free with a recent 
normal repeat electroencephalogram (EEG). He was meeting developmental milestones and there were 
no concerns with vision or hearing. He has ongoing cardiology and hepatology follow-up but has been 
discharged from ophthalmology. In view of the cardiac and ophthalmological findings, he was 
investigated for Alagille syndrome, but genetic analysis was normal; thus, this diagnosis was excluded. 
Furthermore, in view of the unexplained neonatal jaundice, a diagnosis of possible familial 
haemophagocytic lymphohistiocytosis was also considered. His XLP2 expression was comparable with 
a control sample, suggesting that he does not have XLP2. However granule release assay showed absent 
cytotoxic granule release on two occasions, initially suggesting a possible defect in a granule release 
pathway. However subsequent analysis showed no pathogenic mutations present in the genes related to 
FHL3-5, GS2 and XLP2, and so it was presumed that the initial abnormal cytotoxic granule release tests 
had simply reflected his initial newborn state. 
DISCUSSION 
This baby was born in an unexpectedly poor condition with moderate neonatal encephalopathy related to 
perinatal compromise. After review of the case and subsequent investigation, the most likely cause for 
this was fetal compromise due to mild asphyxiation associated with fetal anaemia, which was felt to be 
due to chronic haemolysis secondary to anti-E-related HDFN. 
Anti-E is reported to be the most common non-Rh-D antibody cause of HDFN with a prevalence of 
14%–30%.1–4 Case reports and series in current literature report varying severity of HDFN; however, 
severe cases appear to occur in the context of isolated maternal titres of anti-E >1:16.5–8 For example 
Joy et al 5 reported a series of 32 pregnancies at risk of HDFN from anti-E of which a maternal titre of 
1:32 or greater predicted all anaemic fetuses. In contrast, however, Moran et al 6 reported 122 
pregnancies over a 29-year period in which anti-E was identified as the only maternal autoantibody. Of 
these, 62 pregnancies were affected by HDFN of varying severity (Walker classification 1971), and 
titres ranged from 1/1, that is, where anti-E was only detected using enzyme techniques, to higher titres 
up to 1/1600. Of interest, the single very severe case was associated with a maternal titre of 1/1. 
Moran et al 6 recommended that regardless of maternal anti-E titre, a direct antihuman globulin test and 
haemoglobin measurement should be performed on cord blood, unless the fetus is known to be Rh-E-
negative, which was the action taken in this case. 
Following detection of maternal anti-E antibodies, identification of Rh-E status of the fetus would help 
further stratify which pregnancies are at risk. This, like the current practice for antenatal diagnosis of 
Rh-D status (for Rh-D-negative mothers), can be performed with validated cell-free fetal DNA tests of 
maternal blood, which as well as being a non-invasive method of testing Rh-E status would also avoid 
potential discrepancies in reported paternity as would be the case with paternal phenotyping.9 10  
The current paucity of literature suggests this is a relatively rare case; however, given the severity of the 
haemolysis and significant neonatal adverse resultant effects associated with this earlier low maternal 
anti-E titre, we suggest that more intensive fetal monitoring may be warranted in cases where anti-E 
antibody is detected, irrespective of titre. 
LEARNING POINTS 
• Adherence to current screening guidelines for the management of women with anti-E antibodies 
did not detect a baby, who then suffered moderate neonatal encephalopathy requiring therapeutic 
hypothermia and haemolytic disease of the newborn requiring exchange transfusion. 
• Expectant parents should be reminded of the nature of screening tests, including that there are 
always some false positives and negatives. 
• Consideration should be given when revising the guidelines for antenatal screening for abnormal 
antibodies as to whether the evidence in this area supports a change. 
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